Accordingly, in PNH patients on eculizumab, the extent of C3 binding correlates with reticulocyte count, the in vivo half-life of 51Cr-labeled RBCs is reduced and there is an excess of spleen and liver 51Cr uptake [23]. This evidence concerns the gene C3 and paroxysmal nocturnal hemoglobinuria.